Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ. van Dijk EH, et al. Among authors: kapiteijn eh. Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26. Ophthalmology. 2015. PMID: 26123090 Clinical Trial.
New therapeutic agents in uveal melanoma.
Velho TR, Kapiteijn E, Jager MJ. Velho TR, et al. Anticancer Res. 2012 Jul;32(7):2591-8. Anticancer Res. 2012. PMID: 22753717 Review.
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.
Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM. Melief SM, et al. Among authors: kapiteijn eh. Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073773
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Among authors: kapiteijn eh. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT, Boer FL, van Poelgeest MIE, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Kapiteijn EHW, Haanen JBAG. van Zeijl MCT, et al. Among authors: kapiteijn ehw. Eur J Cancer. 2020 Sep;137:127-135. doi: 10.1016/j.ejca.2020.05.021. Epub 2020 Aug 4. Eur J Cancer. 2020. PMID: 32763783
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven JJM, Haanen JBAG. van Zeijl MCT, et al. Eur J Cancer. 2021 Feb;144:242-251. doi: 10.1016/j.ejca.2020.11.028. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373869
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM, Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM, Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S, Haanen JBAG, van der Veldt AAM. Mulder EEAP, et al. BMC Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. BMC Cancer. 2021. PMID: 33765967 Free PMC article.
Survival of stage IV melanoma in Belgium and the Netherlands.
Suijkerbuijk KPM, Haanen JBAG, Boers-Sonderen MJ, Hospers GAP, Blank CU, van den Berkmortel FWPJ, de Groot JWB, Piersma D, Aarts MJB, van Rijn RS, Vreugdenhil G, Westgeest HM, Kapiteijn E, van der Veldt AAM, van den Eertwegh AJM. Suijkerbuijk KPM, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e118-e119. doi: 10.1111/jdv.17668. Epub 2021 Sep 30. J Eur Acad Dermatol Venereol. 2022. PMID: 34536304 No abstract available.
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken MG, Leeneman B, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Westgeest HM, Wouters MWJM, Haanen JBAG, Uyl-de Groot CA. Franken MG, et al. ESMO Open. 2021 Dec;6(6):100320. doi: 10.1016/j.esmoop.2021.100320. Epub 2021 Nov 29. ESMO Open. 2021. PMID: 34856511 Free PMC article.
79 results